Measuring costs in cost-utility analyses -: Variations in the literature

被引:93
作者
Stone, PW
Chapman, RH
Sandberg, EA
Liljas, B
Neumann, PJ
机构
[1] Univ Rochester, Rochester, NY 14642 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
costs and cost analysis; cost-utility analysis; cost-effectiveness analysis;
D O I
10.1017/S0266462300161100
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Although cost-utility analysis (CUA) has been recommended by some experts as the preferred technique for economic evaluation, there is controversy regarding what costs should be included and how they should be measured. The purpose of this study was to: a) identify the cost components that have been included in published CUAs; b) catalogue the sources of valuation used; c) examine the methods employed for estimating costs; and d) explore whether methods have changed over time, Methods: We conducted a comprehensive search of the published literature and systematically collected data on the cost estimation of CUAs. We audited the cost estimates in 228 CUAs. Results: In most studies (99%), analysts included some direct healthcare costs. However, the inclusion of direct non-healthcare and time costs (17%) was generally lacking, as was productivity costs (8%). Only 6% of studies considered future costs in added life-years. In general, we found little evidence of change in methods over time. The most frequently used source for valuation of healthcare services was published estimates (73%), Few studies obtained utilization data from RCTs (10%) or relied on other primary data (23%). About two-thirds of studies conducted sensitivity analyses on cost estimates. Conclusions: We found wide variations in the estimation of costs in published CUAs. The study underscores the need for more uniformity and transparency in the field, and continued vigilance over cost estimates in CUAs on the pari of analysts, reviewers, and journal editors.
引用
收藏
页码:111 / 124
页数:14
相关论文
共 66 条
[1]   ECONOMIC-ANALYSIS IN RANDOMIZED CONTROL TRIALS [J].
ADAMS, ME ;
MCCALL, NT ;
GRAY, DT ;
ORZA, MJ ;
CHALMERS, TC .
MEDICAL CARE, 1992, 30 (03) :231-243
[2]  
BALADI J, 1998, HEALTH ECON, P221
[3]   Interpreting cost analyses of clinical interventions [J].
Balas, EA ;
Kretschmer, RAC ;
Gnann, W ;
West, DA ;
Boren, SA ;
Centor, RM ;
Nerlich, M ;
Gupta, M ;
West, TD ;
Soderstrom, NS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (01) :54-57
[4]   Analysis and interpretation of cost data in randomised controlled trials: review of published studies [J].
Barber, JA ;
Thompson, SG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7167) :1195-1200
[5]   Methodologic evaluation of the radiology cost-effectiveness literature [J].
Blackmore, CC ;
Magid, DJ .
RADIOLOGY, 1997, 203 (01) :87-91
[6]  
Brouwer WBF, 1997, HEALTH ECON, V6, P253, DOI 10.1002/(SICI)1099-1050(199705)6:3<253::AID-HEC266>3.3.CO
[7]  
2-Y
[8]  
Brouwer WBF, 1997, HEALTH ECON, V6, P511, DOI 10.1002/(SICI)1099-1050(199709)6:5<511::AID-HEC297>3.0.CO
[9]  
2-K
[10]  
Canadian Co-ordinating Office for Health Technology Assessment , 1997, GUID EC EV PHARM CAN